Which has stronger earnings & valuation, ZNTL or TELO?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zentalis Pharmaceuticals N/A N/A -$137.06M -$1.73 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A

Is ZNTL or TELO more profitable?

Zentalis Pharmaceuticals' return on equity of -53.61% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -53.61% -40.67% Telomir Pharmaceuticals N/A -201.23% -172.71%

Do analysts recommend ORGO or TELO?

Organogenesis currently has a consensus target price of $5.75, indicating a potential upside of 143.13%. Given Organogenesis' higher probable upside, research analysts plainly believe Organogenesis is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer LYEL or TELO?

Lyell Immunopharma currently has a consensus target price of $43.20, suggesting a potential upside of 231.03%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Lyell Immunopharma is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate NLTX or TELO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, NLTX or TELO?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A

Is NLTX or TELO more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Telomir Pharmaceuticals N/A -201.23% -172.71%

Do analysts prefer TELO or SNDL?

SNDL has a consensus target price of $5.00, indicating a potential upside of 298.41%. Given SNDL's higher probable upside, analysts plainly believe SNDL is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SNDL 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Telomir Pharmaceuticals (TELO) Competitors

$1.25 +0.04 (+2.89%)

As of 12:03 PM Eastern

Compare

TELO vs. ZNTL, ORGO, LYEL, NLTX, and SNDL

Should you buy Telomir Pharmaceuticals stock or one of its competitors? MarketBeat compares Telomir Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Telomir Pharmaceuticals include Zentalis Pharmaceuticals (ZNTL), Organogenesis (ORGO), Lyell Immunopharma (LYEL), Neoleukin Therapeutics (NLTX), and SNDL (SNDL).

How does Telomir Pharmaceuticals compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Zentalis Pharmaceuticals has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 1 mentions for Zentalis Pharmaceuticals and 0 mentions for Telomir Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Zentalis Pharmaceuticals	Neutral
Telomir Pharmaceuticals	Neutral

Zentalis Pharmaceuticals' return on equity of -53.61% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Zentalis Pharmaceuticals presently has a consensus price target of $6.75, indicating a potential upside of 40.30%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Zentalis Pharmaceuticals is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	N/A	N/A	-$137.06M	-$1.73	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

Summary

Zentalis Pharmaceuticals beats Telomir Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Organogenesis?

Organogenesis (NASDAQ:ORGO) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Organogenesis has higher revenue and earnings than Telomir Pharmaceuticals. Organogenesis is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$512.59M	0.59	$37.03M	-$0.19	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

49.6% of Organogenesis shares are owned by institutional investors. 18.8% of Organogenesis shares are owned by company insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Organogenesis currently has a consensus target price of $5.75, indicating a potential upside of 143.13%. Given Organogenesis' higher probable upside, research analysts plainly believe Organogenesis is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Organogenesis had 3 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for Organogenesis and 0 mentions for Telomir Pharmaceuticals. Organogenesis' average media sentiment score of 0.67 beat Telomir Pharmaceuticals' score of 0.00 indicating that Organogenesis is being referred to more favorably in the media.

Company	Overall Sentiment
Organogenesis	Positive
Telomir Pharmaceuticals	Neutral

Telomir Pharmaceuticals has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Organogenesis has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market.

Summary

Organogenesis beats Telomir Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Lyell Immunopharma?

Lyell Immunopharma (NASDAQ:LYEL) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Lyell Immunopharma currently has a consensus target price of $43.20, suggesting a potential upside of 231.03%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Lyell Immunopharma is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telomir Pharmaceuticals has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Lyell Immunopharma's return on equity of -85.71% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Telomir Pharmaceuticals has lower revenue, but higher earnings than Lyell Immunopharma. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	7,993.13	-$274.45M	-$13.80	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

In the previous week, Lyell Immunopharma's average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Lyell Immunopharma	Neutral
Telomir Pharmaceuticals	Neutral

Lyell Immunopharma has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market.

66.1% of Lyell Immunopharma shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Lyell Immunopharma beats Telomir Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

In the previous week, Neoleukin Therapeutics' average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Telomir Pharmaceuticals	Neutral

Neoleukin Therapeutics' return on equity of -37.22% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Summary

Telomir Pharmaceuticals beats Neoleukin Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to SNDL?

Telomir Pharmaceuticals (NASDAQ:TELO) and SNDL (NASDAQ:SNDL) are related small-cap companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, SNDL had 24 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 24 mentions for SNDL and 0 mentions for Telomir Pharmaceuticals. SNDL's average media sentiment score of 0.02 beat Telomir Pharmaceuticals' score of 0.00 indicating that SNDL is being referred to more favorably in the news media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Neutral
SNDL	Neutral

Telomir Pharmaceuticals has higher earnings, but lower revenue than SNDL. SNDL is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
SNDL	$928.39M	0.35	-$11.29M	-$0.06	N/A

Telomir Pharmaceuticals has a net margin of 0.00% compared to SNDL's net margin of -2.36%. SNDL's return on equity of -2.01% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
SNDL	-2.36%	-2.01%	-1.67%

SNDL has a consensus target price of $5.00, indicating a potential upside of 298.41%. Given SNDL's higher probable upside, analysts plainly believe SNDL is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SNDL	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telomir Pharmaceuticals has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market. Comparatively, SNDL has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

Summary

SNDL beats Telomir Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

Get Telomir Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TELO vs. The Competition

Export

Metric	Telomir Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$84.25M	$3.52B	$6.79B	$12.63B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-4.22	7.39	282.14	25.05
Price / Sales	N/A	1,212.47	573.43	80.07
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	7.21	17.11	11.09	6.19
Net Income	-$10.41M	-$12.56M	$3.49B	$347.61M
7 Day Performance	-0.41%	-0.59%	0.42%	0.74%
1 Month Performance	-3.54%	-7.44%	-4.33%	-3.72%
1 Year Performance	-30.40%	49.84%	63.09%	20.27%

Telomir Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TELO Telomir Pharmaceuticals	0.1486 of 5 stars	$1.25 +2.9%	N/A	-31.3%	$85.63M	N/A	N/A	1	Positive News Gap Down
ZNTL Zentalis Pharmaceuticals	1.6985 of 5 stars	$4.65 +0.7%	$6.75 +45.0%	+253.7%	$331.32M	$67.43M	N/A	160	Upcoming Earnings
ORGO Organogenesis	1.6617 of 5 stars	$2.52 -0.6%	$5.75 +128.6%	-47.5%	$323.63M	$564.17M	N/A	950	Positive News Upcoming Earnings
LYEL Lyell Immunopharma	3.1614 of 5 stars	$12.93 -0.5%	$43.20 +234.1%	+17.4%	$316.81M	$40K	N/A	270
NLTX Neoleukin Therapeutics	N/A	$33.22 -4.0%	N/A	+51.0%	$312.20M	N/A	N/A	90	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TELO) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telomir Pharmaceuticals (TELO) Competitors

TELO vs. ZNTL, ORGO, LYEL, NLTX, and SNDL

How does Telomir Pharmaceuticals compare to Zentalis Pharmaceuticals?

Summary

How does Telomir Pharmaceuticals compare to Organogenesis?

Summary

How does Telomir Pharmaceuticals compare to Lyell Immunopharma?

Summary

How does Telomir Pharmaceuticals compare to Neoleukin Therapeutics?

Summary

How does Telomir Pharmaceuticals compare to SNDL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO vs. The Competition

Telomir Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telomir Pharmaceuticals (TELO) Competitors

TELO vs. ZNTL, ORGO, LYEL, NLTX, and SNDL

How does Telomir Pharmaceuticals compare to Zentalis Pharmaceuticals?

Which has more volatility & risk, ZNTL or TELO?

Does the media favor ZNTL or TELO?

Is ZNTL or TELO more profitable?

Do analysts recommend ZNTL or TELO?

Which has stronger earnings & valuation, ZNTL or TELO?

Summary

How does Telomir Pharmaceuticals compare to Organogenesis?

Which has higher earnings and valuation, ORGO or TELO?

Do insiders & institutionals believe in ORGO or TELO?

Do analysts recommend ORGO or TELO?

Does the media prefer ORGO or TELO?

Is ORGO or TELO more profitable?

Which has more risk and volatility, ORGO or TELO?

Summary

How does Telomir Pharmaceuticals compare to Lyell Immunopharma?

Do analysts prefer LYEL or TELO?

Is LYEL or TELO more profitable?

Which has higher valuation and earnings, LYEL or TELO?

Does the media prefer LYEL or TELO?

Which has more volatility & risk, LYEL or TELO?

Do insiders & institutionals hold more shares of LYEL or TELO?

Summary

How does Telomir Pharmaceuticals compare to Neoleukin Therapeutics?

Which has more risk and volatility, NLTX or TELO?

Do analysts rate NLTX or TELO?

Do insiders and institutionals hold more shares of NLTX or TELO?

Which has preferable valuation & earnings, NLTX or TELO?

Does the media prefer NLTX or TELO?

Is NLTX or TELO more profitable?

Summary

How does Telomir Pharmaceuticals compare to SNDL?

Does the media favor TELO or SNDL?

Which has preferable earnings & valuation, TELO or SNDL?

Is TELO or SNDL more profitable?

Do analysts prefer TELO or SNDL?

Which has more volatility & risk, TELO or SNDL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO vs. The Competition

Telomir Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools